Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization

Publisher： Karger

E-ISSN： 1423-0232|91|6|317-330

ISSN： 0030-2414

Source： Oncology, Vol.91, Iss.6, 2016-10, pp. : 317-330

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602

By Sato Yozo  

Upsala Journal of Medical Sciences, Vol. 118, Iss. 1, 2013-03 ,pp. : 16-22

Informa Healthcare

Access to resources Recommend Favorite

Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma

By  

HEPATOLOGY, Vol. 270-9139, Iss. 4, 2015-10 ,pp. : 1111-1121

John Wiley & Sons Inc

Access to resources Recommend Favorite

Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma

By  

HEPATOLOGY, Vol. 62, Iss. 4, 2015-10 ,pp. : 1111-1121

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation of the mRECIST and α-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib

By  

Oncology, Vol. 83, Iss. 4, 2012-08 ,pp. : 192-200

Karger

Access to resources Recommend Favorite

TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 11, 2015-11 ,pp. : 2466-2473

John Wiley & Sons Inc

Access to resources Recommend Favorite